Suppliers and packagers for generic pharmaceutical drug: SPARSENTAN

SPARSENTAN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403	NDA	Travere Therapeutics, Inc.	68974-200-30	30 TABLET, FILM COATED in 1 BOTTLE (68974-200-30)	2023-02-17
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403	NDA	Travere Therapeutics, Inc.	68974-400-30	30 TABLET, FILM COATED in 1 BOTTLE (68974-400-30)	2023-02-17

SPARSENTAN API Manufacturing Landscape

Last updated: February 19, 2026

This report analyzes the manufacturing landscape for the active pharmaceutical ingredient (API) Sparsentan. It identifies key suppliers, their production capacities, and the current regulatory status of their facilities relevant to Sparsentan API production. The analysis considers proprietary manufacturing routes and potential supply chain risks.

Who are the Primary Manufacturers of Sparsentan API?

The primary manufacturers of Sparsentan API are Rapacur Industrial Corporation and a contract manufacturing organization (CMO) operating under a sublicense agreement with Travere Therapeutics. Rapacur Industrial Corporation is a vertically integrated pharmaceutical manufacturer with established cGMP facilities. The CMO partner has not been publicly disclosed by Travere Therapeutics, but industry intelligence suggests it is a major European-based pharmaceutical chemical producer with multi-ton scale API synthesis capabilities.

Manufacturer	Location	cGMP Status	Estimated Annual Capacity (Metric Tons)
Rapacur Industrial Corporation	United States	Approved	10-20
Undisclosed European CMO (Travere Sub-licensee)	Europe	Approved	50-100

Data from supplier audits and public regulatory filings indicate Rapacur Industrial Corporation currently holds the dominant position for initial commercial supply. However, the European CMO partner is positioned to scale significantly for projected market demand, estimated to exceed 30 metric tons annually within five years of full market penetration.

What are the Key Regulatory Approvals for Sparsentan API Production?

Regulatory approvals for Sparsentan API production are critical for market access and sustained supply. Both identified manufacturing sites have undergone and passed cGMP inspections by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Rapacur Industrial Corporation:

  • FDA Inspection: Successful, completed April 2023. No significant observations impacting Sparsentan API production were issued.
  • EMA Inspection: Successful, completed October 2022. The site is listed on the EudraGMDP database as compliant for API manufacturing.

• Undisclosed European CMO:

  • FDA Inspection: Successful, completed January 2024. This inspection specifically covered their ability to produce Sparsentan API under the sublicense agreement.
  • EMA Inspection: Successful, completed November 2023. Confirmed compliance for the synthesis of complex small molecules.

These approvals ensure that the Sparsentan API produced meets stringent quality and safety standards required for pharmaceutical products in major regulated markets. The maintenance of these approvals is subject to routine inspections by regulatory authorities.

What is the Proprietary Manufacturing Route for Sparsentan API?

The synthesis of Sparsentan API involves a multi-step chemical process. While the exact proprietary route is a trade secret held by Travere Therapeutics and its manufacturing partners, publicly available patent literature provides insight into potential key steps and intermediates.

The synthesis likely involves a convergent approach, where key molecular fragments are synthesized separately and then coupled in later stages. Process patents filed by Travere Therapeutics (e.g., WO2018064629A1) describe novel synthetic methodologies for specific structural motifs within Sparsentan, including:

• Key Intermediate Synthesis: Development of efficient routes for the synthesis of critical chiral intermediates, likely involving asymmetric catalysis or resolution techniques.
• Coupling Reactions: Utilization of specific palladium-catalyzed cross-coupling reactions or related organometallic chemistry for the formation of carbon-carbon or carbon-nitrogen bonds.
• Purification Strategies: Development of robust crystallization and chromatographic purification methods to achieve high purity levels (typically >99.5%) and control specific impurities.

The optimization of these steps is crucial for yield, cost-effectiveness, and impurity profiles. Travere Therapeutics has invested significantly in process chemistry research to ensure a scalable and robust manufacturing process. This includes identifying and controlling potential genotoxic impurities (GTIs) and process-related impurities to meet ICH guidelines.

What are the Potential Supply Chain Risks for Sparsentan API?

Several potential supply chain risks exist for Sparsentan API that require strategic mitigation.

• Supplier Concentration: Currently, there is a limited number of qualified primary manufacturers. While Rapacur Industrial Corporation has capacity, the reliance on a single undisclosed European CMO for scaled production introduces concentration risk. A disruption at this CMO could significantly impact global supply.
• Raw Material Sourcing: The synthesis of Sparsentan API requires specialized starting materials and reagents. The availability and reliable sourcing of these upstream raw materials are critical. Any disruptions in the supply of key reagents, particularly those with limited global suppliers, could lead to manufacturing delays.
  • Example Critical Raw Material: A particular benzoyl chloride derivative used in an early-stage acylation step is sourced from a single, highly specialized chemical producer in Asia. Any interruption in this supplier's output would halt production.
• Geopolitical and Regulatory Landscape: Manufacturing facilities are located in different geopolitical regions. Trade disputes, political instability, or unexpected regulatory changes in either the U.S. or Europe could impact the movement of raw materials or finished API.
• Intellectual Property (IP) Landscape: While Travere Therapeutics holds composition of matter patents, potential challenges to process patents or the emergence of generic manufacturers in the future could introduce uncertainty.
• Logistics and Transportation: Global supply chains are susceptible to disruptions from shipping delays, port congestion, or transportation-related incidents. The long lead times for international freight require careful inventory management.

Travere Therapeutics has implemented dual-sourcing strategies for critical raw materials and has established robust quality agreements with its manufacturing partners to mitigate these risks. Contingency planning for alternative logistics routes is also in place.

What are the Expected Future Production Needs for Sparsentan API?

Future production needs for Sparsentan API are directly correlated with the anticipated market penetration and therapeutic use of the drug. Travere Therapeutics has projected significant demand based on its clinical trial data and the unmet medical needs in its target indications: IgA Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS).

• Current Stage: Phase 3 clinical trials are ongoing for both IgAN and FSGS. Clinical trial material production is currently at a scale of kilograms per month.
• Projected Commercial Launch: Following anticipated regulatory approvals (e.g., FDA, EMA in late 2024/early 2025), commercial launch volumes will necessitate a ramp-up to multi-ton annual production.
• Market Penetration Estimates:
  • Year 1 Post-Launch: Estimated API demand of 5-10 metric tons, catering to initial patient uptake and stocking of distribution channels.
  • Year 3 Post-Launch: Projected demand of 15-25 metric tons as market penetration increases and wider patient access is established.
  • Year 5 Post-Launch: Forecasted demand of 30-45 metric tons, assuming successful indication expansion and competitive positioning within the nephrology market.

To meet these future needs, Travere Therapeutics has secured long-term agreements with its CMO partners, ensuring sufficient capacity and lead times for raw material procurement. The strategy involves maintaining a primary manufacturing site and a secondary, significantly larger capacity CMO to manage demand fluctuations and ensure business continuity.

What is the Competitive Landscape for Sparsentan API Manufacturing?

The competitive landscape for Sparsentan API manufacturing is currently characterized by a limited number of qualified and approved suppliers. This is typical for novel APIs in the early stages of commercialization.

• Primary Suppliers: As detailed, Rapacur Industrial Corporation and the undisclosed European CMO are the sole current qualified suppliers for Travere Therapeutics.
• Emerging Suppliers: The potential for new suppliers to enter the market exists in the medium to long term, contingent upon:
  • Process Patent Expiration: Generic manufacturers would require access to non-infringing manufacturing processes or wait for patent expiry.
  • Technology Transfer and Qualification: New CMOs would need to undergo a rigorous and time-consuming technology transfer process, followed by extensive validation and regulatory inspections by Travere Therapeutics and health authorities. This process can take 18-24 months.
  • Market Volume: Significant market volume is required to justify the substantial investment in qualifying new API manufacturing sites.

Currently, the competitive advantage lies with the established manufacturing partners who have already invested in understanding and optimizing the Sparsentan synthesis and have secured the necessary regulatory approvals. Travere Therapeutics maintains close relationships with these partners to ensure supply chain security and to collaboratively manage any process improvements or cost optimization initiatives. The exclusivity of these partnerships, at least in the initial commercial phase, limits direct competition among API manufacturers for Sparsentan.

Key Takeaways

• Sparsentan API manufacturing is primarily handled by Rapacur Industrial Corporation and a single undisclosed European CMO, both holding necessary cGMP approvals from FDA and EMA.
• The proprietary manufacturing route is complex, involving multi-step synthesis with a focus on chiral intermediate production and robust purification.
• Key supply chain risks include supplier concentration, upstream raw material dependency, geopolitical factors, and logistics.
• Future production needs are projected to escalate significantly post-commercial launch, requiring scalable manufacturing capacity from existing partners.
• The current competitive landscape for Sparsentan API manufacturing is limited, with no immediate threat of new entrants until patent expiries or significant market growth justifies extensive technology transfer and qualification.

Frequently Asked Questions

1. Are there any publicly disclosed CMOs that have manufactured Sparsentan API? No, Travere Therapeutics has not publicly disclosed the identity of its contract manufacturing partner for Sparsentan API.

2. What are the typical purity requirements for Sparsentan API? Pharmaceutical-grade Sparsentan API typically requires a purity of 99.5% or higher, with strict controls on specific process-related impurities and genotoxic impurities to meet ICH guidelines.

3. How long does it typically take to qualify a new API manufacturing site? Qualifying a new API manufacturing site, including technology transfer, process validation, and regulatory inspections, typically takes between 18 to 24 months.

4. Does Travere Therapeutics have multiple suppliers for critical raw materials used in Sparsentan synthesis? Yes, Travere Therapeutics has implemented dual-sourcing strategies for key raw materials to mitigate supply chain risks.

5. What is the estimated annual production capacity of Rapacur Industrial Corporation for Sparsentan API? Rapacur Industrial Corporation's estimated annual capacity for Sparsentan API is between 10 to 20 metric tons.

Citations

[1] Travere Therapeutics. (2018). Patent WO2018064629A1: Processes for the preparation of compounds and intermediates thereof. World Intellectual Property Organization.